Date:11/28/2011

or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to launch beta and full product releases, the Company's ability to obtain FDA concurrence use for anti-microbial coatings in a timely manner; the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Investor Relations:
Liolios Group, Inc.
Scott Li
'/>"/>

SOURCE Bacterin International Holdings, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Bacterin Becomes Premier Founding Sponsor of RMECs New Osteobiologics Registry
2. Bacterin to Present at Lazard Capital Markets 8th Annual Healthcare Conference on November 16, 2011
3. Bacterin Sponsors the 2012 Donate Life Rose Parade Float in Recognition of Donor Families
4. Bacterin International to Present at Stifel Nicolaus 2011 Healthcare Conference on September 8, 2011
5. Bacterin Reports New Hires and Management Reorganization, Driving Most Active Processing Month in July
6. Bacterin International Signs Its Second National GPO Contract for Bacterin Biologics and Its First For Wound Drains with ROi
7. Bacterin International to Present at Noble Financial Capital Markets Seventh Annual Equity Conference on May 16, 2011
8. Bacterin International Secures $1.9 million in Private Placement
9. Bacterin International Updates Fourth Quarter and Full Year 2010 Financial Results
10. Bacterin International Signs LOI to Acquire Assets of Robinson MedSurg LLC
11. Bacterin International Holdings Secures $5,000,000 Credit Facility with Bridge Bank